​

Lyell Immunopharma (LYEL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

LYEL Stock Forecast

Lyell Immunopharma (LYEL) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $6.67, with a high of $12.00 and a low of $1.00. This represents a -48.17% decline from the last price of $12.87.

- $3 $6 $9 $12 $15 High: $12 Avg: $6.67 Low: $1 Last Closed Price: $12.87

LYEL Stock Rating

Lyell Immunopharma stock's rating consensus is Hold, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 0 Buy (0.00%), 4 Hold (80.00%), 1 Sell (20.00%), and 0 Strong Sell (0.00%).

Hold
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

LYEL Price Target Upside V Benchmarks

TypeNameUpside
StockLyell Immunopharma-48.17%
SectorHealthcare Stocks 19.91%
IndustryBiotech Stocks 55.52%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$1.00
Last Closing Price$12.87$12.87$12.87
Upside/Downside---92.23%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 25--3-14
Jun, 25--3-14
May, 25--3-14
Apr, 25--3-14
Mar, 25--3-14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 30, 2024Geoff MeachamBank of America Securities$1.00$0.955.26%-92.23%
Nov 14, 2022Morgan Stanley$7.00$4.5354.53%-45.61%
May 24, 2022Goldman Sachs$12.00$4.01199.25%-6.76%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 24, 2025H.C. WainwrightNeutralNeutralhold
Oct 28, 2024H.C. WainwrightNeutralNeutralhold
Jun 27, 2024H.C. WainwrightNeutraldowngrade
Nov 14, 2022Morgan StanleyEqual-Weightdowngrade
Nov 11, 2022Goldman SachsBuyNeutraldowngrade
May 24, 2022Goldman SachsBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-1.18$-0.02$-0.93$-1.31--
Avg Forecast$-1.47$-0.86$-0.92$-0.75$-0.71$-0.61
High Forecast$-1.47$-0.86$-0.86$-0.74$-0.59$-0.59
Low Forecast$-1.47$-0.87$-0.99$-0.75$-0.86$-0.62
Surprise %-19.73%-97.67%1.09%74.67%--

Revenue Forecast

$0 $17M $34M $51M $68M $85M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$10.65M$84.68M$130.00K---
Avg Forecast$9.41M$49.32M$2.07M$39.20K$32.50K$43.33K
High Forecast$9.41M$49.70M$4.09M$39.20K$32.50K$43.33K
Low Forecast$9.41M$49.14M$57.24K$39.20K$32.50K$43.33K
Surprise %13.19%71.70%-93.73%---

Net Income Forecast

$-400M $-320M $-240M $-160M $-80M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-285.50M$-4.75M$-234.63M$-342.99M--
Avg Forecast$-369.39M$-215.85M$-234.63M$-187.53M$-181.76M$-152.26M
High Forecast$-369.39M$-214.81M$-215.68M$-186.32M$-148.48M$-149.12M
Low Forecast$-369.39M$-217.99M$-248.86M$-188.74M$-215.04M$-155.40M
Surprise %-22.71%-97.80%-82.90%--

LYEL Forecast FAQ

Is Lyell Immunopharma stock a buy?

Lyell Immunopharma stock has a consensus rating of Hold, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 0 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Lyell Immunopharma is a neutral investment for most analysts.

What is Lyell Immunopharma's price target?

Lyell Immunopharma's price target, set by 5 Wall Street analysts, averages $6.67 over the next 12 months. The price target range spans from $1 at the low end to $12 at the high end, suggesting a potential -48.17% change from the previous closing price of $12.87.

How does Lyell Immunopharma stock forecast compare to its benchmarks?

Lyell Immunopharma's stock forecast shows a -48.17% downside, underperforming the average forecast for the healthcare stocks sector (19.91%) and underperforming the biotech stocks industry (55.52%).

What is the breakdown of analyst ratings for Lyell Immunopharma over the past three months?

  • July 2025: 0% Strong Buy, 0% Buy, 75.00% Hold, 0% Sell, 25.00% Strong Sell.
  • June 2025: 0% Strong Buy, 0% Buy, 75.00% Hold, 0% Sell, 25.00% Strong Sell.
  • May 2025: 0% Strong Buy, 0% Buy, 75.00% Hold, 0% Sell, 25.00% Strong Sell.

What is Lyell Immunopharma’s EPS forecast?

Lyell Immunopharma's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.71, marking a -45.80% decrease from the reported $-1.31 in 2024. Estimates for the following years are.

What is Lyell Immunopharma’s revenue forecast?

Lyell Immunopharma's average annual revenue forecast for its fiscal year ending in December 2025 is $32.5K, reflecting a 0% decrease from the reported $0 in 2024. The forecast for.

What is Lyell Immunopharma’s net income forecast?

Lyell Immunopharma's net income forecast for the fiscal year ending in December 2025 stands at $-182M, representing a -47.01% decrease from the reported $-343M in 2024. Projections indicate .